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Background: Integrin α6β4 contributes to cancer progression by stimulating transcription as well as translation of
cancer related genes. Our previous study demonstrated that α6β4 stimulates translation initiation of survival factors
such as VEGF by activating mTOR pathway. However, the immediate early signaling events that link α6β4 to mTOR
activation needs to be defined.
Results: In the current studies, we demonstrated that c-Src is an immediate early signaling molecule that acts
upstream of α6β4 dependent mTOR activation and subsequent translation of VEGF in MDA-MB-435/β4 and MDA-
MB-231 cancer cells. m7GTP-Sepharose–binding assay revealed that Src activity is required to form eIF4F complex
which is necessary for Cap-dependent translation in α6β4 expressing human cancer cells.
Conclusions: Overall, our studies suggest that integrin β4 and c-Src activation is important early signaling events to
lead mTOR activation and cap-dependent translation of VEGF.
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Cancer cells must acquire survival advantages including
growth signaling autonomy, apoptosis resistance, sus-
taining of angiogenesis under stress conditions such as
nutrient and oxygen deprivation to successfully survive
in tumor microenvironment [1]. Although these compli-
cated processes involves regulation of survival related
gene expression both at the transcription and transla-
tional level, recent evidence suggest that translation ini-
tiation is a primary check point that regulates cancer
related mRNAs [2]. One of the major mechanisms that
cancer cells maintain higher efficiency of translation ini-
tiation involves stimulation of translation initiation fac-
tor, eIF4E [3,4].
eIF4E is the rate limiting factor responsible for deliver-
ing cellular mRNAs to eIF4F complex (eIF4E, a scaffold
protein eIF4G and a RNA helicase eIF4A) through inter-
action with the 5’-terminal (m7GpppN) Cap structure of
mRNAs [5]. Most of the cancer related mRNAs have the
highly complex and lengthy 5’ untranslated region,
which leads to the low translation initiation efficiency* Correspondence: Jun-Chung@ouhsc.edu
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reproduction in any medium, provided the or[6]. Therefore, either level or activity of eIF4E needs to
be up regulated to maintain active translation of these
weak mRNAs. One way to enhance eIF4E activity is
through PI3-K/Akt dependent signaling cascade that ac-
tivates mTOR kinase [7]. Activated mTOR phosphory-
lates and inactivates eIF4E-binding protein 4E-BP [7].
Upon phosphorylation of 4E-BP, eIF4E is released from
4E-BP and bind to eIF4G to form eIF4F complex which
mediates translation initiation [7,8]. Aggressive cancer
cells often take advantage of mitogenic signaling path-
ways to activate mTOR and free up eIF4E to maintain
their survival and growth [9-11].
Our previous studies demonstrated that α6β4 integrin
stimulates eIF4E activity to promote translation of sur-
vival factor, VEGF via Akt/mTOR pathway in breast car-
cinoma cells under serum deprivation condition [12,13].
While α6β4-dependent translation control via ATK/
mTOR pathway has been established, the early signaling
event to link between α6β4 and mTOR is not well char-
acterized. One of the prime candidates that mediate
α6β4 dependent mTOR activation is Src as it is a key
immediate early downstream effector of α6β4 and its ac-
tivity is required for α6β4 signaling competency [14,15].
Src is an intracellular non-receptor tyrosine kinase
which has been implicated in proliferation, metastasisLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ample, oestrogen induced c-Src activation leads to 4E-
BP phoshorylation through PI3K/mTOR pathway and
consequently promotes translation of HIF-1 α in breast
cancer cells [18]. Another study showed that active c-Src
up-regulates translation of β-catenin by activation of
eIF4E via Ras/ERK pathway and the phosphorylation of
4E-BP via the PI3K/mTOR pathways [19] Based on
these evidences that c-Src stimulate translational initi-
ation via mTOR signaling, we hypothesized that c-Src
mediates α6β4 dependent mTOR activation and subse-
quent assembly of eIF4E machinery to enhance cap-
dependent translation of weak mRNAs.
In this study, we assessed the role of c-Src in α6β4
dependent translational control. Pharmacologic inhibition
of c-Src as well as knockdown of its expression by shRNA
showed that c-Src plays an essential role in mediating
α6β4 dependent mTOR activation in MDA-MB-435/β4
and MDA-MB-231 cancer cells. Src is also required to
form eIF4F complex and enhance cap-dependent transla-
tion of VEGF mRNA. These results suggest that c-Src is
an important immediate early signaling molecule to con-
nect α6β4 signaling to mTOR, which eventually contrib-
ute to translation of survival factors such as VEGF.
Results
Src activity is required for α6β4 dependent mTOR
phosphorylation
α6β4 plays a pivotal role in controlling translation
through mTOR signaling [13], but the immediate early
signaling events that link α6β4 to mTOR activation re-
mains to be defined. Based on recent reports that c-Src
is involved in translation initiation through AKT/mTOR
signaling in human cancer cells [18,19], we hypothesized
that c-Src is a major mediator for α6β4 dependent
mTOR activation. To test this hypothesis, we first
assessed the relationship between α6β4 expression and
Src activity. We stably knocked down β4 integrin expres-
sion in MDA-MB-231 using lentivirus shRNA. MDA-
MB-435 cells, which endogenously lack β4 expression,
were stably transfected with either β4 integrin or mock
vector (Figure 1A). As reported previously by our studies
and others [14,20], the reduction of β4 integrin expres-
sion by β4 shRNA in MDA-MB-231 cells effectively
blocked Src phosphorylation at Y416 (an indicator of Src
activation) and β4 phosphorylation at Y1494 (an indica-
tor of β4 integrin activation) (Figure 1A. left panel). The
exogenous β4 integrin expression in MDA-MB-435 cells
(MDA-MB-435/β4) significantly increased the Src phos-
phorylation at Y416 (Figure 1A. right panel). We then
tested the role of Src in α6β4 dependent mTOR phos-
phorylation. Pharmacologic inhibition of Src activity by
PP2 effectively decreased phosphorylation level of
mTOR at Ser2448 (an indicator of mTOR activity) inMDA-MB-231 and MDA-MB-435/β4 cells (Figure 1B).
To further confirm the role of Src in α6β4 dependent
mTOR phosphorylation, we knocked down expression
of c-Src using shRNA in MDA-MB-231 and MDA-MB-
435/β4 cells. Knockdown of c-Src expression signifi-
cantly reduces the level of phosphorylated mTOR at
S2448 too (Figure 1C). We were not able to detect a sig-
nificant change of the total protein level of mTOR by in-
hibition of Src by PP2 or shRNA. These data suggest
that α6β4 dependent c-Src activation leads to the phos-
phorylation of mTOR.
c-Src contributes to α6β4 dependent TORC1 and TORC2
activation
Mammalian target of rapamycin (mTOR) exists in two
functionally and structurally distinct complexes, TORC1
and TORC2 [21]. The primary function of TORC1 is to
regulate translation initiation through the phosphoryl-
ation of S6K and 4EBP1, whereas the primary function
of TORC2 is to regulate survival and proliferation by ac-
tivation of the kinases such as AKT and SGK [21,22]. To
assess relative contribution of c-Src in TORC1 vs.
TORC2 activation, we tested the effects of c-Src inhib-
ition on α6β4 dependent Akt phosphorylation at Ser 473
(an indicator of TORC2 activity) and phosphosrylation
of S6 ribosomal protein at Ser235/236 and 4E-BP1 at
Ser65 (indicators of TORC1 activity) in MDA-MB-231
and MDA-MB-435/β4 cells. Inhibition of c-Src activity
by PP2 (Figure 2A) as well as c-Src expression by shRNA
(Figure 2B) effectively reduced the level of phosphory-
lated AKT (on Ser473), S6 ribosomal protein (on
Ser235/236) and 4E-BP1 (on Ser65). These results sug-
gest that c-Src mediates α6β4 dependent TORC1 and
TORC2 activation.
Inhibition of c-Src blocks α6β4 dependent translation of
VEGF mRNA
We then assessed the effects of c-Src inhibition on the
efficiency of overall translation initiation in MDA-MB-
231 and MDA-MB-435/β4 cells by performing polysome
analysis (Figure 3). The mRNA was isolated from these
cells in the presence of either DMSO or PP2, and then
fractionated on a sucrose gradient. As shown in Figure 3,
the polysome analysis separates untranslated complex
(fraction 1 through 3), light polysomes (fraction 4
through 8; poorly translated mRNAs) and heave poly-
somes (fraction 9 through 12; efficiently well-translated
mRNAs). Our previous studies demonstrated that ex-
pression of β4 integrin increases the pool of heavy poly-
somes in these cells [13,21]. The inhibition of Src
activity by PP2 dramatically reduced the amount of
heavy polysomes (Figure 3), suggesting that Src is re-
quired for α6β4 dependent translation initiation. Next,
we tested the role of Src in α6β4 dependent VEGF
AB
C
Figure 1 c-Src mediates α6β4 dependent mTOR activation. (A) MDA-MB-231breast cancer cells (parental, GFP and β4 shRNA infectants) and
MDA-MB-435 human cancer cells (parental, mock and β4 shRNA infectants) were lysed using RIPA buffer. Equal amount of protein were isolated
from extracts of these cell lined for Western blot analysis with indicated antibodies. (B) MDA-MB-231 cells and MDA-MB-435/ β4 cells were incu-
bated with or without various concentration of PP2 for 24 hr before lysis by RIPA buffer. The laysate were analyzed by Western blotting using
antibodies against phospho-mTOR (S2448), mTOR, phospho-Src (Y416), and Src. (C). MDA-MB-231 cells and MDA-MB-435/ β4 cells were infected
with lentivirus that stably expresses either GFP or c-Src shRNA. These cells were lysed with RIPA buffer for Western blot analysis with indicated
antibodies. The intensity of p-mTOR (S2448) band was quantified by densitometric analysis using ImageJ software. The number given underneath
gel image represents fold change compared with control cells. All results are representative of three independent experiments.
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polysomal fraction was analyzed by qRT-PCR. In the
MDA-MB-231 and MDA-MB-435/β4 (Figure 4), VEGF
mRNA is distributed mostly in the polysomal region
(L and H, fractions #4-12). Both PP2 inhibition of Src
activity (Figure 4A) and c-Src knockdown by shRNA
(Figure 4B) effectively shifted the distribution of VEGF
mRNA to untranslated complexes (U, fractions #1-3).
This result indicates that c-Src inhibition affects cap
dependent translation initiation of weak mRNAs such
as VEGF.Inhibition of Src prevents assembly of eIF4F complexes
Since cap-dependent translational efficiency of weak
mRNAs such as VEGF is determined by activity of eIF4E
and the eIF4F complexes, we examined the role of c-Src
in eIF4E-binding to eIF4F components such as eIF4E
and eIF4G. We performed m7GTP-Sepharose pull down
assay in MDA-MB-435/β4 cells to test whether Src in-
hibition modulates the interaction of eIF4E with eIF4G
(an indicator of active translation) or 4E-BP1 (an indica-
tor of inactive translation). The inhibition of Src by PP2
(Figure 5A) and c-Src knockdown by shRNA (Figure 5B)
AB
Figure 2 c-Src is required for α6β4 dependent TORC1 and TORC2 activation. (A) MDA-MB-231 cells and MDA-MB-435/ β4 cells were incu-
bated with DMSO and indicated concentrations of PP2 for 24 hr before lysis by RIPA buffer. Equal amount of protein were isolated and analyzed
by Western blotting using antibodies against phospho-AKT (S473), AKT, phospho-S6 ribosomal protein (S235/236), and phospho-4E-BP1 (S65).
(B) Equal lysates from MDA-MB-231 cells and MDA-MB-435/ β4 cells expressing shRNA against GFP or c-Src were analyzed by Western blotting
with indicated antibodies. The intensity of p-4E-BP1 (S65) band was quantified by densitometric analysis using ImageJ software. The number
given underneath gel image represents fold change compared with control cells. All results are representative of three independent experiments.
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m7GTP, whereas the binding level of 4E-BP1 to eIF4E is
increased. These data suggests that the inhibition of Src
disrupts the assembly of eIF4F complex by inducing the
binding of 4E-BP1 to eIF4E, and by disassociating eIF4G
from eIF4E.
Discussion
A number of studies demonstrated the role of integrins
in translation of survival and growth factors through en-
hancing eIF4E function [12], but the exact mechanism
by which integrins control translation initiation of can-
cer related mRNAs remains to be determined. In the
previous study, we showed that α6β4 integrin promotes
the translation of VEGF mRNA through the AKT/
mTOR/eIF4E signaling axis [13]. In the current studies,
we investigated the role of c-Src as an immediate early
signaling effector that mediates α6β4 dependent mTOR
activation. We provided evidence that c-Src inhibition
by PP2 or shRNA blocks mTOR pathway and the subse-
quent assembly of eIF4F complexes. This is first reportto define the early signaling event that link between
α6β4 and mTOR pathway.
Our studies indicated that c-Src is one of early α6β4
signaling effectors that mediate mTOR activation. As c-
Src represents one isoform of Src Family Kinases (SFKs),
it is possible that other isoform of SFKs could play a role
in α6β4 dependent mTOR activation. This is more likely
due to the previous report that Fyn becomes activated to
mediate α6β4 dependent pro-invasive migration of
breast carcinoma cells [23]. α6β4 dependent Fyn activa-
tion requires the recruitment of SHP2 to the phosphory-
lated cytoplasmic domain of integrin β4 [23]. It remains
to be seen whether α6β4 dependent c-Src activation also
requires the involvement of SHP2. Another possibility is
the involvement of Focal Adhesion Kinase (FAK) in c-
Src activation. FAK was shown to be activated by α6β4
[24] and FAK mediates Src activation in integrin signal-
ing such as α5β1 or α4β1 [25]. If we establish the mech-
anism by which a6b4 activates multiple isoforms of SFKs
including Fyn and c-Src, we may need to perform se-
quential knockdown of each SFK isoform expression by
Figure 3 The effect of Src inhibition on translation initiation. MDA-MB-231 cells and MDA-MB-435/ β4 cells were treated with DMSO or
10 μM PP2 for 24 hr. Cell lysates were separated into 12 fractions on sucrose gradients as described in the Methods. The distribution was continu-
ously recorded by absorbance at A254nm. The polysome profiles were showed as peaks. 1 through 7 represents light polysomes (untranslated
mRNA and initiation complex) and 8 through 12 represents heavy polysomes (translated mRNA). Numbers indicates fraction numbers. The results
are obtained from three independent experiments.
Soung et al. BMC Cell Biology 2013, 14:49 Page 5 of 9
http://www.biomedcentral.com/1471-2121/14/49shRNAs to test the role of other SFKs in mTOR activa-
tion. The assays will test whether multiple SFK isoform
synergistically contribute to α6β4 dependent mTOR ac-
tivation, or the loss of one SFK isoform could simply be
compensated by others.
While our current studies mostly focused on transla-
tion initiation aspects of mTOR signaling (mostly
through TORC1 pathway), TORC2 pathway is likely acti-
vated by α6β4/c-Src signaling axis (Figure 2B). Enhance-
ment of eIF-4E function by α6β4 is known to be
mediated by TORC1 pathway as we previously showed
that TORC1 specific inhibitor, rapamycin blocked α6β4
dependent eIF-4E activation [13]. It remains to be deter-
mined how TORC2 signaling pathway contributes to
α6β4 dependent phenotypes of breast carcinoma cells
such proliferation, survival, cell motility and invasion.
Knockdown of TORC2 specific components such as Ric-
tor or Sin1 [26,27] will address this issue.
It is currently unknown how activated c-Src by α6β4
mediates downstream signaling events leading to mTOR
activation. Both Akt and MAPK seem to be prime candi-
dates in mediating c-Src dependent mTOR activation as
both involves 4E-BP1 phosphorylation, which is a key
event for mTOR activation [19,28]. Activated Src was
shown to mediate both Akt [29] and MAPK [30]. Alter-
natively, c-Src could enhance the functional crosstalk be-
tween α6β4 and growth factor receptors such as EGFRand c-Met [31] and this interaction was shown to en-
hance both Akt [32] and MAPK signaling [33]. All these
evidences suggest that c-Src could be an important
therapeutic target that could affect growth factor recep-
tor signaling as well as downstream events such as
mTOR signaling. Considering that the role of α6β4 in
breast carcinoma progression is well established, but no
therapeutic agent against α6β4 is available yet, targeting
Src activity will merit consideration against tumors that
express high levels of α6β4.
Conclusions
In conclusion, we defined that c-Src is an immediate
early signaling molecule that connects α6β4 to mTOR
signaling axis. c-Src mediates α6β4 dependent mTOR
activation and subsequent enhancement of cap-dependent
translation of weak mRNAs such as VEGF. Our finding
suggests that c-Src could be an important target of therapy
for tumors that express high levels of α6β4.
Methods
Cell lines and cultures
The MDA-MB-231 human breast carcinoma cells and
MDA-MB-435 human cancer cells were obtained from
the Lombardi Breast Cancer Depository at Georgetown
University. The generation of MDA-MB-435 subclones























































































































































Figure 4 Src activity is required for α6β4 dependent VEGF translation. Whole cell lysates were prepared from MDA-MB-231 cells and MDA-
MB-435/β4 cells treated with DMSO or 10 μM PP2 overnight (A) and infected with GFP or c-Src shRNA (B). The relative VEGF mRNA content of
each sucrose gradient fraction was measured by Real time PCR and normalized to GFP mRNA (external control) as described in the Methods. The
data are represented as the mean ratio of VEGF to β- actin mRNA (± SD) obtained from triplicate samples. The statistical analysis was done using
Student’s t-test. * P < 0.05, **P < 0.01. U, untranslated complexes (fractions #1-3); L, light polyribosomes (fractions #4-8); H, heavy polyribosomes
(fractions #9-12).
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AB
Figure 5 Src activity is required for eIF-4 F complex. MDA-MB-231 cells and MDA-MB-435/ β4 cells treated with DMSO or PP2 (A) and
infected with either GFP- or Src-shRNA (B) were lysed and then incubated with m7GTP-Sepharose beads. The eluted proteins were analyzed by
immunoblotting with antibodies against eIF4G, eIF4E and 4E-BP. The graphs on the right side of each panel represent the mean ratio of 4E-BP1
to eIF4E in triplicate samples (± SD). The statistical analysis was done using Student’s t-test. * P < 0.05, **P < 0.01.
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scribed [13]. MDA-MB-231 cells were stably infected
with lentivirus that expressed shRNA targeted against β4
integrin or Src and MDA-MB-435/β4 cells were infected
against Src as previously described [20]. GFP shRNA
was used as control and puromycin (2 μg/ml) was used
for the selection of infected cells. Cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM)/low
glucose (Hyclone, Logan, UT) supplemented with 10%
fetal bovine serum and 1% penicillin-streptomycin (Gibco,
Carlsbad, CA).
Antibodies and reagents
The integrin β4 (clone H-101) and actin (clone C-11) anti-
bodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA), and the p-mTOR (S2448), p-Src (Y416),
p-Akt (S473), p-S6 ribosomal protein (S235/236), p-4E-
BP1 (S65), 4E-BP1, mTOR, Src (clone 36D10), and Akt
antibodies were obtained from Cell Signaling Technology
(Beverly, MA). Also, integrin β4 (Y1494, phospho-
specific) antibody was obtained from ECM bioscience
(Versailles, KY) and PP2 (Src kinase inhibitor) was pur-
chased from EMD chemicals Inc. (San Diego, CA). The
antibodies against eIF4G and eIF4E were kindly provided
by Dr. Rhoads (LSUHSC, Shreveport). For the pharmaco-
logical inhibition, cells were incubated with or without10–50 μM PP2 for 24 hours before lysis for Western blot
analysis.
Western blot analysis
Cells were lysed using 50 mM Tris buffer, pH 7.4, con-
taining 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, 0.1% SDS, 1 mM sodium orthovanadate, 5 mM
EDTA, 1 mM phenylmethylsulfonyl fluoride, and 1%
protease inhibitor (Pierce, Rockford, IL) and scraped,
collected, and then protein concentration was deter-
mined using BCA protein assay kit (Pierce, Rockford,
IL). Total protein was resolved on the 4-20% gradient
SDS-PAGE, transferred to polyvinylidene fluoride mem-
branes and incubated with a primary antibody. After
three 10 min washes in 50 mM Tris buffer, pH 7.5, con-
taining 0.15 M NaCl and 0.1% Tween-20, protein was
detected, in turn, by means of a peroxidase - or alkaline
phoaphatase - conjugated secondary antibody and
visualized using the Luminol and Oxidizing solutions
(Boston Bioproducts, Worcester, MA) or BCIP/NBT
Color development substrate (Promega, Madison, WI).
Ribosome fractionation
The MDA-MB-231 cells and MDA-MB-435/β4 cells
were maintained in low serum (0.5% FBS) medium and
then pretreated with 0.1% DMSO (as a solvent for PP2)
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MDA-MB-435/β4 cells were infected with lentivirouses
expressing GFP- or Src shRNA. Before cell lysis, cells
were treated with 50 μg/ml cycloheximide (VWR) and
then incubated for 5–10 min at 37°C. After washing with
PBS containing 100 μg/ml cycloheximide, cells were
lysed in 0.5 ml buffer containing 50 mM Tris–HCl
(pH 7.5), 100 mM KCl, 10 mM MgCl2, 0.5% NP-40,
2 mM DTT, 100 μg/ml cycloheximide, 50 μg/ml heparin,
RNasin 0.5 U/μl (Applied Biosystems), and Complete™
EDTA-free protease inhibitor cocktail (Roche), incubated
on ice for 10 min and centrifuged for 5 min at 10,000 × g,
4°C. The supernatants were collected and frozen at −80°C.
One hundred μg aliquots of total lysates were used for
m7GTP-Sepharose binding experiments. An equal volume
of lysate was applied to a 15 to 45% (w/v) sucrose gradient
containing 100 μg/ml cycloheximide and then centrifuged
in a Beckman SW41Ti rotor at 38,000 rpm at 4°C for 3 h.
Gradients were fractionated (1 ml) and then monitored
for absorbency at 254 nm using an ISCO syringe pump
with UV-6 detector.
RNA preparation and quantitative real time PCR
Before RNA isolation, four hundred aliquots from each
fraction after ribosome fractionation were spiked with
100 pg of GFP mRNA (internal control). Then, the RNA
was purified from using an E.Z.N.A. Total RNA Kit
(Omega bio-tek) according to manufacturer’s instruc-
tions. Reverse transcription was performed with random
primers and reverse transcriptase from the TaqMan® Re-
verse Transcription Reagents kit (Applied Biosystems)
following the manufacturer’s protocol. Quantitative real
time PCR was used to measure the GFP and VEGF
mRNAs level in each fraction. Amplification and detec-
tion were performed using the iCycler IQ Real-time PCR
detection system with IQ™ SYBRgreen Supermix (Bio-
Rad). The VEGF mRNA levels were normalized with the
GFP internal control. Then, relative amount of VEGF in
each fraction was expressed as a percentage of the sum
of this mRNA in all fractions. To assist statistical signifi-
cance of the changes in the VEGF mRNA redistribution
along the sucrose density gradients, the percentage of
VEGF mRNA co-sedimented with untranslated complexes
(U, fractions #1-3), light polyribosomes, containing weakly
translated mRNA (fractions #4-8) or heavy polyribosomes,
containing efficiently translated mRNAs (H, fractions #9-
12), was calculated as a sum of VEGF mRNA in the corre-
sponding fractions from the original data.
Protein binding assays on m7GTP-sepharose
One hundred μg of lysates were prepared as described in
the “Ribosome Fractionation” section and then diluted
in equal volume of buffer containing 50 mM Tris–HCl
(pH 7.5) and 2 mM DTT. The samples were mixed with50 μl m7GTP-Sepharose (GE Healthcare), 50% slurry in
buffer containing 20 mM Tris–HCl (pH 7.5), 100 mM
KCl, 1 mM DTT, and 10% (v/v) glycerol. After 2 h incu-
bation at 4°C with rotation, the resin was washed three
times with 200-μl aliquots of buffer B. Proteins were
eluted in 20 μl SDS-electrophoresis buffer and analyzed
by Western blotting. To assist statistical significance of
the changes in the eIF4E and 4EBP1 binding, the bands
of corresponding proteins were scanned and analyzed
with ImageQuant TL software.
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